MMS Holdings

MMS Holdings — Not a curated data product but a services exhaust: sponsor-owned protocol-adjacent datasets assembled case-by-case for external/synthetic control arm construction, plus the far larger byproduct of the company's risk-management and patient-support program operations — longitudinal patient-level data collected at scale while running regulated safety-program and adherence programmes for pharmaceutical clients (enrolment, dispensing, adherence, outcomes, survey/professional data). Oncology clinical trial data management and biometrics deliverables (cleaned SDTM/ADaM-domain datasets…

MMS Holdings offers (Alternative, Fundamental, Reference) — Not disclosed. Bounded read from scale proxies: a ~$608M revenue provider with ~980 staff running regulated programmes and biometrics for large-pharma clients implies patient-level data across many millions of programme enrolments and thousands of studies cumulatively — but every one of those records is sponsor-contracted, so no single aggregate corpus is available to a buyer.

External/synthetic control arm construction for oncology and rare-disease programmes; trial feasibility and eligibility-criteria optimisation; regulatory real-world evidence submissions; statistical-power and sample-size simulation; benchmarking of competitor treatment patterns; adherence and persistence modelling for commercial and market-access teams; training/evaluation of models that predict trial eligibility or disease progression

The data is with 20 years of history.

Coverage spans US; Health Care Technology; alternative, fundamental, reference; equities.